Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Saved in:
| Title: | Efficacy, safety, and immunogenicity of the AS01 |
|---|---|
| Authors: | Ison MG; Bethesda, MD, USA., Papi A; Pulmonary Division, University of Ferrara, St Anna University Hospital, Ferrara, Italy., Athan E; Barwon Health, University Hospital Geelong, Geelong, VIC, Australia; Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, VIC, Australia., Feldman RG; Senior Clinical Trials, Laguna Hills, CA, USA., Langley JM; Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, NS, Canada., Lee DG; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Leroux-Roels I; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium., Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; Genetics, Vaccines, Infectious Diseases, and Pediatrics Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain., Schwarz TF; Institute of Laboratory Medicine and Vaccination Center, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany., van Zyl-Smit RN; Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa., Cuadripani S; GSK, Stevenage, UK., Deraedt Q; GSK, Wavre, Belgium., Dezutter N; GSK, Wavre, Belgium., Gerard C; GSK, Rixensart, Belgium., Fissette L; GSK, Wavre, Belgium., Xavier S; GSK, Bengaluru, India., David MP; GSK, Wavre, Belgium., Olivier A; GSK, Wavre, Belgium., Van der Wielen M; GSK, Wavre, Belgium. Electronic address: marie.x.van-der-wielen@gsk.com., Descamps D; GSK, Wavre, Belgium. |
| Corporate Authors: | AReSVi-006 study group |
| Source: | The Lancet. Respiratory medicine [Lancet Respir Med] 2025 Jun; Vol. 13 (6), pp. 517-529. Date of Electronic Publication: 2025 Apr 14. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40245915 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy, safety, and immunogenicity of the AS01<subscript>E</subscript>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ison+MG%22">Ison MG</searchLink>; Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Papi+A%22">Papi A</searchLink>; Pulmonary Division, University of Ferrara, St Anna University Hospital, Ferrara, Italy.<br /><searchLink fieldCode="AU" term="%22Athan+E%22">Athan E</searchLink>; Barwon Health, University Hospital Geelong, Geelong, VIC, Australia; Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Feldman+RG%22">Feldman RG</searchLink>; Senior Clinical Trials, Laguna Hills, CA, USA.<br /><searchLink fieldCode="AU" term="%22Langley+JM%22">Langley JM</searchLink>; Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Lee+DG%22">Lee DG</searchLink>; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Leroux-Roels+I%22">Leroux-Roels I</searchLink>; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.<br /><searchLink fieldCode="AU" term="%22Martinon-Torres+F%22">Martinon-Torres F</searchLink>; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; Genetics, Vaccines, Infectious Diseases, and Pediatrics Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Schwarz+TF%22">Schwarz TF</searchLink>; Institute of Laboratory Medicine and Vaccination Center, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22van+Zyl-Smit+RN%22">van Zyl-Smit RN</searchLink>; Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Cuadripani+S%22">Cuadripani S</searchLink>; GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Deraedt+Q%22">Deraedt Q</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Dezutter+N%22">Dezutter N</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Gerard+C%22">Gerard C</searchLink>; GSK, Rixensart, Belgium.<br /><searchLink fieldCode="AU" term="%22Fissette+L%22">Fissette L</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Xavier+S%22">Xavier S</searchLink>; GSK, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22David+MP%22">David MP</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Olivier+A%22">Olivier A</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+der+Wielen+M%22">Van der Wielen M</searchLink>; GSK, Wavre, Belgium. Electronic address: marie.x.van-der-wielen@gsk.com.<br /><searchLink fieldCode="AU" term="%22Descamps+D%22">Descamps D</searchLink>; GSK, Wavre, Belgium. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22AReSVi-006+study+group%22">AReSVi-006 study group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101605555%22">The Lancet. Respiratory medicine</searchLink> [Lancet Respir Med] 2025 Jun; Vol. 13 (6), pp. 517-529. <i>Date of Electronic Publication: </i>2025 Apr 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101605555 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2213-2619 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222132600%22">22132600 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Respir Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40245915 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2213-2600(25)00048-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 517 Titles: – TitleFull: Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ison MG – PersonEntity: Name: NameFull: Papi A – PersonEntity: Name: NameFull: Athan E – PersonEntity: Name: NameFull: Feldman RG – PersonEntity: Name: NameFull: Langley JM – PersonEntity: Name: NameFull: Lee DG – PersonEntity: Name: NameFull: Leroux-Roels I – PersonEntity: Name: NameFull: Martinon-Torres F – PersonEntity: Name: NameFull: Schwarz TF – PersonEntity: Name: NameFull: van Zyl-Smit RN – PersonEntity: Name: NameFull: Cuadripani S – PersonEntity: Name: NameFull: Deraedt Q – PersonEntity: Name: NameFull: Dezutter N – PersonEntity: Name: NameFull: Gerard C – PersonEntity: Name: NameFull: Fissette L – PersonEntity: Name: NameFull: Xavier S – PersonEntity: Name: NameFull: David MP – PersonEntity: Name: NameFull: Olivier A – PersonEntity: Name: NameFull: Van der Wielen M – PersonEntity: Name: NameFull: Descamps D IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2025 Jun Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2213-2619 Numbering: – Type: volume Value: 13 – Type: issue Value: 6 Titles: – TitleFull: The Lancet. Respiratory medicine Type: main |
| ResultId | 1 |
